Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rationale for a Phase I Trial of Erlotinib and the mTOR inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer

Rationale for a Phase I Trial of Erlotinib and the mTOR inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer. Clinical Cancer Research. 2007; (13):4628-4631.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.